# Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors

> **NCT04672876** · PHASE2 · WITHDRAWN · sponsor: **University of Chicago**

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** Telotristat Ethyl Oral Tablet

## Key facts

- **NCT ID:** NCT04672876
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-01
- **Primary completion:** 2022-10-01
- **Final completion:** 2023-10-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Trial funding no longer available.
- **Last updated:** 2021-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04672876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04672876, "Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04672876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*